SCHEMBL4758478

SCHEMBL4758478

COc1cc2cnc(Oc3ccc4[nH]c(C)cc4c3)nc2cc1OC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.44
PDE4A P27815 2/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
CHEK2 O96017 1/20 0.42
PIK3CD O00329 3/20 0.40
PIK3CA P42336 2/20 0.40
PIK3CB P42338 2/20 0.40
PIK3CG P48736 2/20 0.40
BRAF P15056 1/20 0.39
CACNB4 O00305 1/20 0.39
CACNA1A O00555 1/20 0.39
CACNA1G O43497 1/20 0.39
CACNG3 O60359 1/20 0.39
CACNA1F O60840 1/20 0.39
CACNA1H O95180 1/20 0.39
CACNB3 P54284 1/20 0.39
CACNA2D1 P54289 1/20 0.39
CACNG7 P62955 1/20 0.39
CACNA1B Q00975 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL665930 0.84 BRAF (0.55) PDE4BPDE4APDE4CPDE4DPIK3CD
SCHEMBL666409 0.78 BRAF (0.55) PDE4BPDE4APDE4CPDE4DPIK3CD
SCHEMBL4374447 0.75 BRAF (0.48) CHEK2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL4380906 0.75 RAF1 (0.48) CHEK2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL4380695 0.74 BRAF (0.47) CHEK2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL662774 0.72 KDR (0.57) PDE4BPDE4APDE4CPDE4DCHEK2
SCHEMBL4375565 0.71 FGFR2 (0.45) MEN1KMT2A
SCHEMBL666851 0.71 KDR (0.52) CHEK2BRAF
SCHEMBL5017339 0.70 CHEK2 (0.44) PDE4BPDE4APDE4CPDE4DCHEK2
SCHEMBL6364911 0.69 EGFR (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058342-A1 Quinazoline Derivatives As Angiogenesis Inhibitors ASTRAZENECA AB (SE) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058342-A1 Quinazoline Derivatives As Angiogenesis Inhibitors VEGFA, KDR, FLT1 PDE4B 3267/4885PDE4A 3014/4885PDE4C 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.